1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Mirati’s New CEO Clears Out Execs Ahead Of Key Filing And Readout

Keytruda Combo Data Next Week

 
• By Andrew McConaghie

The biotech could have the best-in-class KRAS inhibitor, but the departure of two senior executives has given investors the jitters as Mirati heads towards its first regulatory filing.

Mirati
The San Diego-based company is set to file adagrasib with the US regulator by the end of 2021. • Source: Alamy

Mirati Therapeutics, Inc.’s newly arrived CEO David Meek has decided to remove two senior executives just weeks before its files its much-anticipated KRAS inhibitor adagrasib with the US Food and Drug Administration.

Meek took the helm just six weeks ago but has apparently concluded that chief medical officer Joseph Leveque and chief operating officer Daniel Faga were not the right

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.